BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Thorax

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/thorax.2003.009290PMID 14760156PMCID PMC1746929
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preventing hospital admissions for COPD: role of physical activity

  2003cited by this paper
• Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.

  2002cited by this paper
• Statement on malignant mesothelioma in the United Kingdom

  2001cited by this paper
• Statement on malignant mesothelioma in the United Kingdom.

  2001cited by this paper
• Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

  2000cited by this paper
• Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

  1999cited by this paper
• The European mesothelioma epidemic

  1999cited by this paper
• Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.

  1998cited by this paper
• A review of chemotherapy trials for malignant mesothelioma.

  1998cited by this paper
• EORTC QLQ-C30 Scoring Manual

  1995cited by this paper
• Continuing increase in mesothelioma mortality in Britain.

  1995cited by this paper
• Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

  1993cited by this paper
• Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.

  1987cited by this paper
• Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.

  1985cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper

• Psychosocial Needs of People Living With Pleural Mesothelioma and Family Carers: A Mixed Methods Study

  2024cites this paper
• Malignant peritoneal mesothelioma interactome with 417 novel protein–protein interactions

  2021cites this paper
• Management of malignant pleural effusions.

  2020cites this paper
• Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

  2019cites this paper
• The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.

  2018cites this paper
• Pain control in thoracic oncology

  2017cites this paper
• Chapter 46 – Uncommon Thoracic Tumors

  2016cites this paper
• The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial

  2015cites this paper
• Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.

  2015cites this paper
• Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

  2015cites this paper
• How are palliative care cancer populations characterized in randomized controlled trials? A literature review.

  2014cites this paper
• Management Options for Malignant Pleural Mesothelioma

  2012influential citation
• Uncommon Thoracic Tumors

  2011cites this paper
• Schmerztherapie bei onkologischen Patienten

  2009cites this paper
• The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

  2009cites this paper
• Update on Pleural Disease: Introduction

  2008cites this paper
• Malignes Pleuramesotheliom und maligne Pleuraergüsse

  2008cites this paper
• Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

  2008cites this paper
• [Environmental cancer: malignant pleural mesothelioma].

  2008cites this paper
• Malignes Pleuramesotheliom und maligne Pleuraergüsse

  2008cites this paper
• Malignant mesothelioma

  2008cites this paper
• Advances in the systemic therapy of malignant pleural mesothelioma

  2008cites this paper
• Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma

  2007cites this paper
• [Update of pemetrexed in thoracic oncology].

  2007cites this paper
• Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.

  2007cites this paper
• Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.

  2007cites this paper
• Assessment of tumor response in malignant pleural mesothelioma.

  2007cites this paper
• [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic].

  2007cites this paper
• Emerging drugs for mesothelioma

  2007cites this paper
• Management options for malignant pleural mesothelioma: clinical and cost considerations.

  2007cites this paper
• Multidisciplinary treatment of malignant pleural mesothelioma.

  2007cites this paper
• Mésothéliome pleural malin

  2007cites this paper
• Le mésothéliome pleural malin : incertitudes et espoirs face à une épidémie annoncée

  2007cites this paper
• BTS statement on malignant mesothelioma in the UK, 2007

  2007cites this paper
• Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

  2007cites this paper
• Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.

  2006cites this paper
• 4.2. Chimiothérapie du mésothéliome pleural malin

  2006cites this paper
• 5.2 Mésothéliome pleural malin : Prise en charge de la dyspnée

  2006cites this paper
• Staging in malignant mesothelioma.

  2006cites this paper
• Prognostic Value of Pleural Fluid pH in Malignant Epithelial Mesothelioma after Talc Poudrage

  2006cites this paper
• A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

  2006cites this paper
• Systemic chemotherapy in the management of malignant peritoneal mesothelioma.

  2006cites this paper
• Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

  2005cites this paper
• Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

  2005cites this paper
• An overview of chemotherapy for mesothelioma.

  2005cites this paper
• Chemotherapy options and new advances in malignant pleural mesothelioma.

  2005cites this paper
• Overview on ongoing or planned clinical trials in Europe.

  2005cites this paper
• Prognostic factors for mesothelioma.

  2005cites this paper
• Management of malignant pleural effusions

  2005cites this paper
• Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case series

  2005cites this paper
• A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.

  2005cites this paper
• Mesothelioma from the patient's perspective.

  2005cites this paper
• Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

  2005cites this paper
• Progress in the management of malignant pleural mesothelioma

  2005cites this paper
• Therapeutische Optionen beim malignen Pleuramesotheliom

  2005cites this paper
• Serie: Pleuraerkrankungen (6) Therapeutische Optionen beim malignen Pleuramesotheliom

  2005cites this paper
• Pleural mesothelioma: little evidence, still time to do trials.

  2004cites this paper
• British Thoracic Society Winter Meeting 2001

  2002cites this paper